Men suffering from enlarged prostate disease were prescribed drugs that would specifically target the androgen receptor (AR). While developing the drug, the following considerations were deliberated on:

A. Drugs should target the N-terminal domain of the AR.
B. Drugs should not target the NLS domain of the AR.
C. The drug should bind to the ligand-binding domain of the AR.
D. The drug should activate CYP17A1 to facilitate conversion of pregnenolone to DHEA.

Which one of the following combinations of considerations will develop the best drug for treatment of enlarged prostate?

Correct option is D

Sol.

• The androgen receptor (AR) has multiple domains: the N-terminal domain (NTD), the DNA-binding domain (DBD), the nuclear localization signal (NLS), and the ligand-binding domain (LBD).

• Drugs targeting the ligand-binding domain (C) block androgen binding, preventing AR activation and are effective in prostate disease treatment.

• Recent research suggests targeting the N-terminal domain (A) is promising because it plays a critical role in AR transcriptional activity and may overcome resistance seen with LBD-targeted drugs.

• Targeting the NLS domain (B) is generally avoided due to potential interference with AR nuclear import and off-target effects.

• Activating CYP17A1 (D) would increase androgen synthesis, worsening the condition, so it’s undesirable.

Information Booster:

• Traditional antiandrogens bind the LBD to inhibit AR function.

• The NTD is intrinsically disordered but critical for AR's transcriptional regulation, making it a novel drug target.

• Targeting both NTD and LBD may provide synergistic inhibition of AR in prostate cancer and enlargement.